A carregar...
Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist
BACKGROUND: Anti(α)-programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) monotherapy fails to provide durable clinical benefit for most patients with carcinoma. Recent studies suggested that strategies to reduce immunosuppressive cells, promote systemic T-cell responses and lymphocyte tr...
Na minha lista:
| Publicado no: | J Immunother Cancer |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7204804/ https://ncbi.nlm.nih.gov/pubmed/32303618 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000493 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|